CD152 Inhibitors:阻害薬のグローバル市場2015(薬開発、治験動向)

◆英語タイトル:CD152 Inhibitors -Pipeline Insights, 2015
◆商品コード:DIMRMOA5187
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2015年版(※最新版はお問い合わせください)
◆ページ数:25以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥133,750見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s,“CD152 Inhibitors-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under CD152 Inhibitors. This report provides information on the therapeutic development based on the CD152 Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

[Data Sources]

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.


• The report provides a snapshot of the global therapeutic landscape of CD152 Inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the CD152 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for CD152 Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

【レポートの目次】

• CD152 Inhibitors Overview
• CD152 Inhibitors Disease Associated
• CD152 Inhibitors Pipeline Therapeutics
• CD152 Inhibitors Therapeutics under Development by Companies
• CD152 Inhibitors Late Stage Products (Filed and Phase III)
• Comparative Analysis
• CD152 Inhibitors Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• CD152 Inhibitors Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• CD152 Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• CD152 Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• CD152 Inhibitors – Discontinued Products
• CD152 Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for CD152 Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

• Number of Products under Development for CD152 Inhibitors by Therapy Area, 2015
• Number of Products under Development for CD152 Inhibitors, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• CD152 Inhibitors Assessment by Monotherapy Products
• CD152 Inhibitors Assessment by Combination Products
• CD152 Inhibitors Assessment by Route of Administration
• CD152 Inhibitors Assessment by Stage and Route of Administration
• CD152 Inhibitors Assessment by Molecule Type
• CD152 Inhibitors Assessment by Stage and Molecule Type
• CD152 Inhibitors Therapeutics – Discontinued Products
• CD152 Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2015

• Number of Products under Development for CD152 Inhibitors by Therapy Area, 2015
• Number of Products under Development for CD152 Inhibitors, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• CD152 Inhibitors Assessment by Monotherapy Products
• CD152 Inhibitors Assessment by Combination Products
• CD152 Inhibitors Assessment by Route of Administration
• CD152 Inhibitors Assessment by Stage and Route of Administration
• CD152 Inhibitors Assessment by Molecule Type
• CD152 Inhibitors Assessment by Stage and Molecule Type

【レポートのキーワード】

薬剤、医薬品、製薬企業、試験、作用機序(MOA)、パイプライン、開発

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[CD152 Inhibitors:阻害薬のグローバル市場2015(薬開発、治験動向)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆